TMEM63C

Across TCGA pan-cancer cohorts, TMEM63C Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM63C data layer compared with 23 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher TMEM63C Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TMEM63C expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUSC, HNSC, and SKCM are the cancer types where TMEM63C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.079	0.792	<.001	30	view →
HNSC	OS	Median	All	0.156	0.710	.003	18	view →
SKCM	DFS	Median	II,III,IV	0.801	0.550	.007	14	view →
COAD	OS	Median	IV	0.045	0.659	<.001	12	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TMEM63C–LUSC (DFS)

Open the LUSC breakdown →